JP2015172090A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015172090A5 JP2015172090A5 JP2015135830A JP2015135830A JP2015172090A5 JP 2015172090 A5 JP2015172090 A5 JP 2015172090A5 JP 2015135830 A JP2015135830 A JP 2015135830A JP 2015135830 A JP2015135830 A JP 2015135830A JP 2015172090 A5 JP2015172090 A5 JP 2015172090A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- antigen
- transplant
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 58
- 230000000694 effects Effects 0.000 claims 24
- 230000027455 binding Effects 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 claims 13
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 13
- 239000003018 immunosuppressive agent Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 229940124589 immunosuppressive drug Drugs 0.000 claims 10
- 230000028993 immune response Effects 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 206010052779 Transplant rejections Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 229930105110 Cyclosporin A Natural products 0.000 claims 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 4
- 108010036949 Cyclosporine Proteins 0.000 claims 4
- 229960001265 ciclosporin Drugs 0.000 claims 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 4
- 229960002930 sirolimus Drugs 0.000 claims 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims 3
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96202207P | 2007-07-25 | 2007-07-25 | |
| US60/962,022 | 2007-07-25 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110577A Division JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016052050A Division JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015172090A JP2015172090A (ja) | 2015-10-01 |
| JP2015172090A5 true JP2015172090A5 (enExample) | 2016-05-12 |
Family
ID=40001380
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518230A Pending JP2010534243A (ja) | 2007-07-25 | 2008-07-25 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2015135830A Pending JP2015172090A (ja) | 2007-07-25 | 2015-07-07 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518230A Pending JP2010534243A (ja) | 2007-07-25 | 2008-07-25 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8252285B2 (enExample) |
| EP (1) | EP2178561A1 (enExample) |
| JP (4) | JP2010534243A (enExample) |
| KR (1) | KR20100041849A (enExample) |
| AU (1) | AU2008279619B2 (enExample) |
| BR (1) | BRPI0814644A2 (enExample) |
| CA (1) | CA2697159C (enExample) |
| MX (1) | MX2010000981A (enExample) |
| WO (1) | WO2009014745A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534243A (ja) * | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| MX2012009321A (es) * | 2010-02-11 | 2012-11-21 | Alexion Pharma Inc | Metodos terapeuticos que utilizan anticuerpos anti-cd200. |
| JP6150734B2 (ja) * | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用 |
| EP3150632B1 (en) | 2011-06-10 | 2020-04-08 | Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence | Anti-ricin antibodies and uses thereof |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| US9737598B2 (en) * | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2018102594A1 (en) * | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| EP3911357A1 (en) | 2019-01-14 | 2021-11-24 | Regents of the University of Minnesota | Cd200ar ligands for cancer immunotherapy |
| EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| DK1032662T3 (da) * | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| WO2004060295A2 (en) | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| NZ599035A (en) * | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| CA2694121C (en) | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
-
2008
- 2008-07-25 JP JP2010518230A patent/JP2010534243A/ja active Pending
- 2008-07-25 EP EP08794745A patent/EP2178561A1/en not_active Withdrawn
- 2008-07-25 BR BRPI0814644-6A2A patent/BRPI0814644A2/pt not_active IP Right Cessation
- 2008-07-25 US US12/670,379 patent/US8252285B2/en not_active Ceased
- 2008-07-25 US US14/080,457 patent/USRE46323E1/en not_active Expired - Fee Related
- 2008-07-25 AU AU2008279619A patent/AU2008279619B2/en not_active Ceased
- 2008-07-25 MX MX2010000981A patent/MX2010000981A/es active IP Right Grant
- 2008-07-25 KR KR1020107003921A patent/KR20100041849A/ko not_active Abandoned
- 2008-07-25 WO PCT/US2008/009037 patent/WO2009014745A1/en not_active Ceased
- 2008-07-25 CA CA2697159A patent/CA2697159C/en not_active Expired - Fee Related
-
2012
- 2012-06-26 US US13/533,546 patent/US8637014B2/en active Active
-
2013
- 2013-05-27 JP JP2013110577A patent/JP5926702B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-07 JP JP2015135830A patent/JP2015172090A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052050A patent/JP2016117762A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015172090A5 (enExample) | ||
| CN111511765B (zh) | 抗半乳凝素-9抗体及其用途 | |
| JP2010534243A5 (enExample) | ||
| JP6242808B2 (ja) | 所望の特異性を有するモノクローナル自己抗体を提供する方法 | |
| JP5926702B2 (ja) | Ｃｄ２００に対する抗体および免疫応答への使用 | |
| Zaza et al. | Monoclonal antibody therapy and renal transplantation: focus on adverse effects | |
| WO2008137915A3 (en) | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
| AU2014220777B2 (en) | Anti-CD26 antibodies and uses thereof | |
| JP2014505056A5 (enExample) | ||
| RU2015145543A (ru) | Способы и композиции для лечения болезни дего | |
| ES2341341T3 (es) | Anticuerpos terapeuticos humanizados contra las isoformas cd45. | |
| RU2017118985A (ru) | Антитела, их применение и способы применения | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2007529196A5 (enExample) | ||
| US20240082305A1 (en) | Anti-c4d chimeric antigen receptor regulatory t cells and uses thereof | |
| JP2019508448A (ja) | 移植片対宿主病予防の方法 | |
| JP2024028850A (ja) | 抗ｐｄ－ｌ１抗体及びその製薬用途 | |
| Broeders et al. | Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. | |
| Cibrik et al. | Role of Anti—Interleukin-2 Receptor Antibodies in Kidney Transplantation | |
| JP2025066696A (ja) | 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用 | |
| JP6881658B2 (ja) | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| Sulemanjee et al. | The first year post–heart transplantation: Use of immunosuppressive drugs and early complications | |
| US20210395343A1 (en) | Ivig composition and method of treatment of antibody deficient patients | |
| Webster | The addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients | |
| Alnimri et al. | The Anti‐Interleukin 2 Receptor Antibodies |